These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17136583)

  • 21. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions.
    Bagi P; Biering-Sørensen F
    Scand J Urol Nephrol; 2004; 38(6):495-8. PubMed ID: 15841785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overactive bladder: prospects and limitations of botulinum toxin].
    Scheiner D; Perucchini D; Fink D
    Gynakol Geburtshilfliche Rundsch; 2006; 46(3):88-95. PubMed ID: 16778447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods.
    Safari S; Jamali S; Habibollahi P; Arshadi H; Nejat F; Kajbafzadeh AM
    Urology; 2010 Jul; 76(1):225-30. PubMed ID: 20110117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum toxin in urinary incontinence.
    Patterson JM; Chapple CR
    Curr Opin Urol; 2006 Jul; 16(4):255-60. PubMed ID: 16770124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB).
    Mohee A; Khan A; Harris N; Eardley I
    BJU Int; 2013 Jan; 111(1):106-13. PubMed ID: 22672569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
    Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
    J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity.
    Reitz A; Schurch B
    J Urol; 2004 Feb; 171(2 Pt 1):804; discussion 804-5. PubMed ID: 14713822
    [No Abstract]   [Full Text] [Related]  

  • 30. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis.
    Baumann L; Slezinger A; Halem M; Vujevich J; Martin LK; Black L; Bryde J
    Int J Dermatol; 2005 May; 44(5):418-24. PubMed ID: 15869543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What role does botulinum toxin play in the treatment of benign prostatic hyperplasia?].
    Mazdar A; Bedouche A; Zoughari S; Ibrahimi A; Sayegh HE; Iken A; Benslimane L; Nouini Y
    Pan Afr Med J; 2016; 24():309. PubMed ID: 28154664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Failure of botulinum toxin injection for neurogenic detrusor overactivity: Switch of toxin versus second injection of the same toxin.
    Peyronnet B; Castel-Lacanal E; Manunta A; Roumiguié M; Marque P; Rischmann P; Gamé X
    Int J Urol; 2015 Dec; 22(12):1160-5. PubMed ID: 26391575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical use of non-A botulinum toxins: botulinum toxin type B.
    Dressler D; Eleopra R
    Neurotox Res; 2006 Apr; 9(2-3):121-5. PubMed ID: 16785108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical comparison of botulinum toxin in motor and autonomic disorders: Similarities and differences.
    Naumann M
    Toxicon; 2015 Dec; 107(Pt A):68-71. PubMed ID: 26143736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical botulinum type-A toxin (Dysport®) in the treatment of idiopathic detrusor overactivity in children.
    Blackburn SC; Jones C; Bedoya S; Steinbrecher HA; Malone PS; Griffin SJ
    J Pediatr Urol; 2013 Dec; 9(6 Pt A):750-3. PubMed ID: 23036518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.
    Vadoud-Seyedi J; Simonart T
    Br J Dermatol; 2007 May; 156(5):986-9. PubMed ID: 17286630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
    Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
    Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum toxin type B for treatment of axillar hyperhidrosis.
    Dressler D; Adib Saberi F; Benecke R
    J Neurol; 2002 Dec; 249(12):1729-32. PubMed ID: 12529798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.